Lin, C.M., et al., Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
When you suddenly cut that fuel supply by 40% to 50%, your body initially struggles to adapt
Market Competition Effects Compounding Market Dynamics: 2022 (Limited Competition): Few providers High prices ($599-$899/month) Significant barriers to entry 2023-2024 (Expanding Competition): More providers entered Prices declined ($399-$699/month) Technology platforms launched 2025-2026 (Mature Competition): Numerous providers Price competition fierce Prices stabilized ($349-$699/month) Quality differentiation emerging Competitive market drives prices toward efficient levels while maintaining quality
Strategies for Keeping the Weight Off After Stopping GLP-1 Medications When patients stop GLP-1 medications like Wegovy or Zepbound, its common for hunger to return and weight regain to begin
The Trigger: The "Brownout" When your brain's demand for energy outstrips its supply of ATP (cellular fuel), the system panics
Kucinskas and colleagues leveraged tirzepatide, one of a new class of effective anti-obesity medications that target GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
,aspect=ignore)
